Theriva Biologics (FRA:SFY0) Cyclically Adjusted PB Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SFY0 Theriva Biologics Inc FRA:SFY0
28 GF Score
Price €2.42
! 3 Warning Signs
View Full Analysis

What is Theriva Biologics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theriva Biologics  (FRA:SFY0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Theriva Biologics Cyclically Adjusted PB Ratio Related Terms


Theriva Biologics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Theriva Biologics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics Cyclically Adjusted PB Ratio Chart

Theriva Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.02 0.05 0.02 0.02

Theriva Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.01 0.02 0.00

FRA:SFY0 vs BIVI, BCLI, LNAI: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Theriva Biologics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Cyclically Adjusted PB Ratio falls into.


FRA:SFY0
28GF Score
Theriva Biologics Inc FRA:SFY0
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theriva Biologics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Theriva Biologics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Theriva Biologics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.29/330.2130*330.2130
=0.290

Current CPI (Mar. 2026) = 330.2130.

Theriva Biologics Quarterly Data

Book Value per Share CPI Adj_Book
201606 204.200 241.018 279.770
201609 -398.800 241.428 -545.458
201612 280.385 241.432 383.490
201703 184.769 243.801 250.258
201706 286.600 244.955 386.353
201709 -938.533 246.819 -1,255.640
201712 -84.267 246.524 -112.874
201803 -172.267 249.554 -227.946
201806 -370.200 251.989 -485.120
201809 -152.381 252.439 -199.328
201812 160.323 251.233 210.724
201903 112.652 254.202 146.337
201906 67.194 256.143 86.625
201909 1.463 256.759 1.882
201912 -39.493 256.974 -50.749
202003 -66.465 258.115 -85.030
202006 -87.733 257.797 -112.377
202009 -92.797 260.280 -117.730
202012 -50.897 260.474 -64.524
202103 126.633 264.877 157.869
202106 120.263 271.696 146.165
202109 118.057 274.310 142.116
202112 109.633 278.802 129.849
202203 97.427 287.504 111.900
202206 92.025 296.311 102.554
202209 88.279 296.808 98.215
202212 80.871 296.797 89.976
202303 73.873 301.836 80.818
202306 60.928 305.109 65.941
202309 56.535 307.789 60.654
202312 49.410 306.746 53.190
202403 42.096 312.332 44.506
202406 26.854 314.175 28.225
202409 8.481 315.301 8.882
202412 6.545 315.605 6.848
202503 5.153 319.799 5.321
202506 1.017 322.561 1.041
202509 0.557 324.800 0.566
202512 0.368 324.054 0.375
202603 0.290 330.213 0.290

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theriva Biologics Business Description

Other Exchanges TOVX:USA
Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
28GF Score

Get the complete analysis for FRA:SFY0

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.42
Price